Survival Motor Neuron Protein (Component Of Gems 1 or Gemin-1 or SMN1 or SMN2) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Survival Motor Neuron Protein (Component Of Gems 1 or Gemin-1 or SMN1 or SMN2) - Pipeline Review, H1 2016

Survival Motor Neuron Protein (Component Of Gems 1 or Gemin-1 or SMN1 or SMN2) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Survival Motor Neuron Protein (Component Of Gems 1 or Gemin-1 or SMN1 or SMN2) - Pipeline Review, H1 2016
Published Jun 30, 2016
76 pages — Published Jun 30, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Survival Motor Neuron Protein (Component Of Gems 1 or Gemin-1 or SMN1 or SMN2) - Pipeline Review, H1 2016, provides in depth analysis on Survival Motor Neuron Protein (Component Of Gems 1 or Gemin-1 or SMN1 or SMN2) targeted pipeline therapeutics.

The report provides comprehensive information on the Survival Motor Neuron Protein (Component Of Gems 1 or Gemin-1 or SMN1 or SMN2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Survival Motor Neuron Protein (Component Of Gems 1 or Gemin-1 or SMN1 or SMN2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Survival Motor Neuron Protein (Component Of Gems 1 or Gemin-1 or SMN1 or SMN2)
- The report reviews Survival Motor Neuron Protein (Component Of Gems 1 or Gemin-1 or SMN1 or SMN2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Survival Motor Neuron Protein (Component Of Gems 1 or Gemin-1 or SMN1 or SMN2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Survival Motor Neuron Protein (Component Of Gems 1 or Gemin-1 or SMN1 or SMN2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Survival Motor Neuron Protein (Component Of Gems 1 or Gemin-1 or SMN1 or SMN2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gai

  
Source:
Document ID
GMDHC0323TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents25
  List of Tables61
  List of Figures61
Introduction71
  Global Markets Direct Report Coverage71
Survival Motor Neuron Protein (Component Of Gems 1 or Gemin-1 or SMN1 or SMN2) Overview81
Therapeutics Development93
  Survival Motor Neuron Protein (Component Of Gems 1 or Gemin-1 or SMN1 or SMN2) Products under Development by Stage of Development91
  Survival Motor Neuron Protein (Component Of Gems 1 or Gemin-1 or SMN1 or SMN2) Products under Development by Therapy Area101
  Survival Motor Neuron Protein (Component Of Gems 1 or Gemin-1 or SMN1 or SMN2) Products under Development by Indication111
Survival Motor Neuron Protein (Component Of Gems 1 or Gemin-1 or SMN1 or SMN2) Pipeline Products Glance122
  Late Stage Products121
  Early Stage Products131
Survival Motor Neuron Protein (Component Of Gems 1 or Gemin-1 or SMN1 or SMN2) Products under Development by Companies142
Survival Motor Neuron Protein (Component Of Gems 1 or Gemin-1 or SMN1 or SMN2) Products under Development by Universities/Institutes162
Survival Motor Neuron Protein (Component Of Gems 1 or Gemin-1 or SMN1 or SMN2) Therapeutics Assessment186
  Assessment by Monotherapy/Combination Products181
  Assessment by Mechanism of Action191
  Assessment by Route of Administration202
  Assessment by Molecule Type222
Survival Motor Neuron Protein (Component Of Gems 1 or Gemin-1 or SMN1 or SMN2) Companies Involved in Therapeutics Development2410
  AveXis, Inc.241
  Bioblast Pharma Ltd.251
  F. Hoffmann-La Roche Ltd.261
  Genethon271
  Genzyme Corporation281
  Ionis Pharmaceuticals, Inc.291
  Novartis AG301
  Sarepta Therapeutics, Inc.311
  Voyager Therapeutics, Inc.321
  WAVE Life Sciences Ltd.331
Survival Motor Neuron Protein (Component Of Gems 1 or Gemin-1 or SMN1 or SMN2) Drug Profiles3426
  ALB-111 Drug Profile341
  Antisense Oligonucleotide to Activate SMN2 for Spinal Muscular Atrophy Drug Profile351
  AVXS-101 Drug Profile363
  azithromycin Drug Profile391
  Gene Therapy to Activate SMN for Spinal Muscular Atrophy Drug Profile401
  Gene Therapy to Activate SMN1 for Spinal Muscular Atrophy Drug Profile411
  Gene Therapy to Activate SMN1 for Spinal Muscular Atrophy Drug Profile421
  LMI-070 Drug Profile431
  nusinersen Drug Profile446
  Oligonucleotides to Activate SMN2 for Spinal Muscular Atrophy Drug Profile501
  PMO-25 Drug Profile511
  RG-7800 Drug Profile522
  RG-7916 Drug Profile541
  Small Molecules for Spinal Muscular Atrophy Drug Profile551
  Small Molecules to Activate SMN2 for Spinal Muscular Atrophy Drug Profile561
  Small Molecules to Activate SMN2 for Spinal Muscular Atrophy Drug Profile571
  Small Molecules to Activate Survival Motor Neuron Protein for Spinal Muscular Atrophy Drug Profile581
  VYSMN-101 Drug Profile591
Survival Motor Neuron Protein (Component Of Gems 1 or Gemin-1 or SMN1 or SMN2) Dormant Projects601
Survival Motor Neuron Protein (Component Of Gems 1 or Gemin-1 or SMN1 or SMN2) Featured News &Press Releases6114
  May 16, 2016: AveXis Presents Pulmonary Data from Ongoing Phase 1 Trial of AVXS-101 in Spinal Muscular Atrophy Type 1611
  May 06, 2016: AveXis Reports Data from Ongoing Phase 1 Trial of AVXS-101 in Spinal Muscular Atrophy Type 1622
  Apr 25, 2016: AveXis to Report Data from Ongoing Phase 1 Clinical Trial of AVXS-101 in Spinal Muscular Atrophy Type 1641
  Apr 21, 2016: Ionis Pharmaceuticals Reports Data Update from Nusinersen Phase 2 Study in Infants with Spinal Muscular Atrophy and Reviews Neurological Disease Franchise641
  Mar 31, 2016: Ionis Pharmaceuticals Advances Nusinersen in the Ongoing SHINE Study in Patients with SMA651
  Jan 12, 2016: Ionis Pharmaceuticals Completes Target Enrollment for Nusinersen Phase 3 Study, CHERISH, in Children with Spinal Muscular Atrophy661
  Jan 07, 2016: Spinal Muscular Atrophy Program Advances with Additional Product Candidate Entering Clinical Development671
  Jan 04, 2016: AveXis Announces Completed Enrollment of Phase 1 Clinical Trial for AVXS-101 in Spinal Muscular Atrophy Type 1671
  Oct 15, 2015: Isis Pharmaceuticals Initiates SHINE Study to Provide ISIS-SMN for Patients With SMA Who Have Completed the Phase 3 ENDEAR and CHERISH Studies681
  Oct 05, 2015: Data from Ongoing Study of AVXS-101 in Spinal Muscular Atrophy Type 1 Presented at World Muscle Congress691
  Oct 04, 2015: Phase 2 Data from Spinal Muscular Atrophy Program Presented at the 20th International Annual Congress of the World Muscle Society701
  Jul 14, 2015: Isis Pharmaceuticals Earns $2.15M for Advancing ISIS-SMN in Children With Spinal Muscular Atrophy711
  Jun 23, 2015: AveXis Gains Orphan Drug Designation From the European Medicines Agency for Gene Therapy Treatment in Spinal Muscular Atrophy721
  Jun 22, 2015: Isis Pharmaceuticals Reports Data from ISIS-SMN Rx in Children with Spinal Muscular Atrophy721
  Jun 22, 2015: BioBlast Announces Positive Preclinical Proof-Of-Concept Results Of Its Novel Read- through Platform in Spinal Muscular Atrophy732
Appendix752
  Methodology751
  Coverage751
  Secondary Research751
  Primary Research751
  Expert Panel Validation751
  Contact Us751
  Disclaimer761

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Survival Motor Neuron Protein (Component Of Gems 1 or Gemin-1 or SMN1 or SMN2) - Pipeline Review, H1 2016" Jun 30, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Survival-Motor-Neuron-Protein-Component-Of-Gems-1-or-Gemin-1-or-SMN1-or-SMN2-Pipeline-Review-H1-2016-2088-16144>
  
APA:
Global Markets Direct - Market Research. (2016). Survival Motor Neuron Protein (Component Of Gems 1 or Gemin-1 or SMN1 or SMN2) - Pipeline Review, H1 2016 Jun 30, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Survival-Motor-Neuron-Protein-Component-Of-Gems-1-or-Gemin-1-or-SMN1-or-SMN2-Pipeline-Review-H1-2016-2088-16144>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.